The beneficial effect of probiotics is based on their ability to modify the gut microflora, stimulate growth and modulate the immune response. In particular, probiotics regulate the expression of inflamation-related and immune-related cytokines and therefore are key players in mantaining intestinal homeostasis. They have been effectively used in the prevention and therapy of digestive tract diseases in poultry farms. In the present research, the immumnomodulatory effects of the probiotic Lactobacillus fermentum BiocenolTMCCM7514 were studied in the caecum of broiler chickens. One-day-old chicks were randomly allocated in two equally divided experimental groups of 30 individuals (n=30): C (control group), no probiotic added, and LF (probiotic group) containing L. fermentum 109 CFU/g in 200 μL. Bacteria were administered per os on daily basis from day 1 to 7. Samples from the caecum were collected on day 8, and mRNA levels of pro-inflammatory (CXCL12, IL16, LIF) and anti-inflammatory cytokines (IL15, IL17RA and IL13) were determined. Exposure to the probiotic significantly reduced mRNA levels of inflammation-related cytokines (*P<0.05) and of some immune-related cytokines (IL15 and IL17RA) (***P<0.001). IL13 was the only cytokine found to be up-regulated (*P<0.05). These results suggest that administration of L. fermentum BiocenolTMCCM7514 have stabilizing effects on intestinal homeostasis by down-regulating crucial cytokines.
DVM. Miroslava Šefcová - internal doctoral candidate at the Institute of Pathological Anatomy of University of Veterinary Medicine and Pharmacy in Košice. Scientific interests: morphometric and molecular methods. Current investigator in the project VEGA n. 1/0112/18-˝Monitoring the immunological properties of new potential probiotic lactobacilli in vitro and in vivo conditions of Campylobacter jejuni infection in chickens”. The doctoral programm includes a foreign internship for examining foodborne diseases and antibacterial resistance in Quito, Ecuador.
Background and Aim: Rheumatoid arthritis (RA) is the most common autoimmune disease. Immunological factors such as T-regs and IL-17 are associated with pathogenesis of RA. Mesenchymal stem cells (MSCs) have recently drawn the attention as a therapeutic choice for the treatement of autoimmune diseases. The aim of our study was to evaluate the effect of intravenous injection of autologous bone marrow-derived MSCs on T-regs and interacellular level of IL-17A in patients with RA.
Methods: Thirteen female patients with RA enrolled in our study. One million autologous bone marrow-derived MSCs/kg was transfused to patients intravenously. Percentage of T-regs and interacellular level of IL-17A were assesed by flow cytometry analysis in 0,1,6 and 12 months. This study was registered in IRCT (IRCT2015102824760N1) and ClinicalTrials.gov (identifier: NCT03333681).
Results: A significant negative correlation (Correlation coefficient= -0.742, P= 0.004) was found between T-regs and IL-17A. Our results showed that by decreasing of T-regs, the level of IL-17A was increased at 12 months.
Conclusion: Insufficinet dose of MSCs and/or lack of replication of autologous injection might have caused this negative correlation between T-regs and IL-17A as time passing from the beginning to 12 months. While T-regs percentage was decreased, their immunomodulatory effects of these cells on IL-17A producing cells seems to be fade out and the balance in the immune system was consequently shifted towrds the inflammation. Increasing in the number of injection and/or dose of MSCs might help to improve the the immunomodulatory effects of MSCs for treatment of RA.
Mojgan Mohammadi has completed her Ph.D. from immunology departement in the University of Manchester, Manchester, UK and postdoctoral fellow from Queen Marry University, London, UK. She is associate professor and medical faculty in Mashhad University of Medical Sciences, Mashhad, Iran and she has puplished more than 25 papers in reputed journals. Her major interest in field of research is performing the clinical trials to explore the novel theraputic effects on the immune system for the treatment of autoimmune and inflammatory diseases.
CCK is a linear hormone that exists in multiple molecular forms. CCK8 is the classic cerebral and intestinal form. In intestinal mucosa several mechanisms have been developed to control antigens of the diet, synthesis of IgA is strategy to generate immunoprotection in the organism. There is little information about "CCK-SIgA" relationship. The purpose of this study was to determinate the effect of CCK on IgA production. For this, a single dose was administered of 8 μg/kg of CCK8, and saline to male BALB/c mice, which were sacrificed 30 minutes later to obtain fecal fluids for quantifying total IgA and SIgA concentration by ELISA. The percentage of IgA+, IgM+ B cell, IgA+ plasma cells (PC) and T cells producers cytokines (IL-2, 4, 5, 6, 10, TGF-β) related to IgA production were determined in lamina propria by FCM. An increase in the total IgA and SIgA concentration is shown in CCK group. Total IgA increase was dependent on the CCK´s concentration. On the other hand, there was an increase of IgA+ B cell (40.0%), IgM+ (21.0%) vs control group (27.5% and 12.0%, respectively) and increase in IgA+ PC percentage (27.0%) vs control group (21.0%). Similarly, in T cell producers cytokines percentage, CCK8 increased IL-2 (5.4%), IL-4 (5.8%), IL-6 (3.2%), IL-10 (4.8 %) vs control group (3.1%, 5.6%, 2.1%, 3.6%, respectively). Results suggest CCK regulates the intestinal immune response by increasing cytokine related to IgA synthesis produced by T cells, could be through the participation of the CCK1 and CCK2 receptors